Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

By D. Planchard, E. Smit, H. Groen, J. Mazières, B. Besse, Å. Helland, V. Giannone, A. D'amelio, Pingkuan Zhang, B. Mookerjee and 1 more. The Lancet Oncology, 2016

987 citations recorded by the source corpus.

Subfields: Molecular Biology, Organic Chemistry, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2bfe3c43c15c52f4fae1ffc4bea4335b9e72f35d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Malone
2. M. Oliva
3. P. Sabatini
4. L. Siu
5. T. Stockley

Citations in the corpus

• Molecular profiling for precision cancer therapies (2020, background): “1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University Avenue, University of Toronto, Toronto, Ontario M5G 1Z5, Canada Full list of author information is available at the end of the article Androgen receptor (AR) A”